Aurora Cannabis Inc. (ACB)

Aurora Cannabis is on track for its first profitable year, driven by a strategic pivot to high-margin medical cannabis and disciplined cost management. Strong international medical sales, improved mar...

As of June 2025, the U.S. cannabis industry continues its rapid expansion. Projections estimate the market will reach approximately $45 billion in revenue this year. This growth is fueled by increasin...

ACB's 30% YTD rally reflects Q3 strength, but flat EPS estimates and consumer weakness keep analysts cautious about long-term upside.

Aurora Cannabis remains a bullish opportunity due to its cheap valuation and an improving business model, despite recent stock weakness. International medical cannabis sales are growing, especially in...

Marijuana stocks hold lots of potential for home-run investments in the future. In 2018, most pot stocks saw their first wave of the green rush. Yet over the last several years, this has not been the ...

When it comes to finding marijuana stocks to buy a happy medium or silver lining at this time is tough to do. Not becuase the low share prices from some of the top-performing companies dont look appet...

Top Canadian cannabis stocks are attracting attention this week as investors seek opportunities in a rapidly evolving industry. Companies like Cronos Group, SNDL Inc., and Aurora Cannabis continue str...

Marijuana stocks have been facing a downward trend in the market for some time. A big reason is regulatory uncertainty and reform issues. Legislative changes, particularly in major markets like the U....

ACB capitalizes on the rapidly evolving medical cannabis landscape, leveraging its EU GMP-certified manufacturing facilities, advanced genetics and deep regulatory knowledge.

Here is how Aurora Cannabis Inc. (ACB) and Concentra Group (CON) have performed compared to their sector so far this year.